WallStSmart

ResMed Inc (RMD)vsUtah Medical Products Inc (UTMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 13914% more annual revenue ($5.40B vs $38.52M). UTMD leads profitability with a 29.3% profit margin vs 27.5%. RMD appears more attractively valued with a PEG of 1.39. RMD earns a higher WallStSmart Score of 70/100 (B).

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34

UTMD

Hold

48

out of 100

Grade: D+

Growth: 2.0Profit: 8.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued
UTMDSignificantly Overvalued (-173.3%)

Margin of Safety

-173.3%

Fair Value

$23.32

Current Price

$63.71

$40.39 premium

UndervaluedFair: $23.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

UTMD3 strengths · Avg: 9.0/10
Operating MarginProfitability
31.1%10/10

Strong operational efficiency at 31.1%

Profit MarginProfitability
29.3%9/10

Keeps 29 of every $100 in revenue as profit

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

UTMD4 concerns · Avg: 2.3/10
Market CapQuality
$204.39M3/10

Smaller company, higher risk/reward

PEG RatioValuation
4.252/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-6.4%2/10

Earnings declined 6.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bull Case : UTMD

The strongest argument for UTMD centers on Operating Margin, Profit Margin, Price/Book. Profitability is solid with margins at 29.3% and operating margin at 31.1%.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : UTMD

The primary concerns for UTMD are Market Cap, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

RMD profiles as a mature stock while UTMD is a declining play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.89 — expect wider price swings.

RMD is growing revenue faster at 11.0% — sustainability is the question.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RMD scores higher overall (70/100 vs 48/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Utah Medical Products Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The company is headquartered in Midvale, Utah.

Want to dig deeper into these stocks?